Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction
Open Access
- 1 June 2015
- journal article
- research article
- Published by Elsevier in JACC: Heart Failure
- Vol. 3 (6) , 487-496
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Chronic Baroreflex Activation Effects on Sympathetic Nerve Traffic, Baroreflex Function, and Cardiac Haemodynamics in Heart Failure: A Proof-of-Concept StudyEuropean Journal of Heart Failure, 2014
- Heart Disease and Stroke Statistics—2014 UpdateCirculation, 2014
- 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive SummaryCirculation, 2013
- Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trialJournal of the American Society of Hypertension, 2012
- Chronic Baroreflex Activation: A Potential Therapeutic Approach to Heart Failure With Preserved Ejection FractionJournal of Cardiac Failure, 2011
- Sympathetic Nervous System Activation in Human Heart FailureJACC, 2009
- Adverse Mortality Effect of Central Sympathetic Inhibition with Sustained-Release Moxonidine in Patients with Heart Failure (MOXCON)European Journal of Heart Failure, 2003
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 1999
- Depressed Heart Rate Variability as an Independent Predictor of Death in Chronic Congestive Heart Failure Secondary to Ischemic or Idiopathic Dilated CardiomyopathyThe American Journal of Cardiology, 1997
- Carvedilol Produces Dose-Related Improvements in Left Ventricular Function and Survival in Subjects With Chronic Heart FailureCirculation, 1996